

03-16-06

TEW 1614

CASE ON/4-32739A



**FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10**

EV727274651US  
Express Mail Label Number

March 15, 2006  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF  
ALL-ERICSSON ET AL.  
INTERNATIONAL APPLICATION NO: PCT/EP03/11601  
FILED: 20 OCTOBER 2003  
U.S. APPLICATION NO: 10/531,967  
35 USC §371 DATE: 13 SEPTEMBER 2005  
FOR: TREATMENT OF UVEAL MELANOMA

**MS: Amendment**  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**


Sir:

This paper is supplemental to the Information Disclosure Statement filed April 20, 2006. Since Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, no fees are believed to be required under 37 C.F.R. §1.97(b)(3). If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449. Copies of these references are enclosed herewith. The references cited on the attached British Search Report were previously cited in the Information Disclosure Statement dated April 20, 2005. US 5,521,184 corresponds to EP 0564403 which was previously cited in the Information Disclosure Statement dated April 20, 2005.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

  
\_\_\_\_\_  
Lydia T. McNally  
Attorney for Applicants  
Reg. No. 36,214

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7898

Date: *March 15, 2006*

(Use several sheets if necessary)

ATTY. DOCKET NO.  
ON/4-32739A  
APPLICATION NO.  
10/531,967  
APPLICANT  
ALL-ERICSSON ET AL.  
FILING DATE  
SEPTEMBER 13, 2005

Group

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	TRADEMARK OFFICE	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	5,521,184	5/28/96	Zimmermann			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES <input type="checkbox"/> NO <input type="checkbox"/>
	AM						<input type="checkbox"/> <input type="checkbox"/>
	AN						<input type="checkbox"/> <input type="checkbox"/>
	AO						<input type="checkbox"/> <input type="checkbox"/>
	AP						<input type="checkbox"/> <input type="checkbox"/>
	AQ						<input type="checkbox"/> <input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Mouriaux et al., "Implication of Stem Cell Factor in the Proliferation of Choroidal Melanocytes," Exp. Eye Res. 73, pp. 151-157 (2001)
AS	May, C. Albrecht, "Mast cell heterogeneity in the human uvea," Histochem Cell Biol, Vol. 112, pp. 381-386 (1999)
AT	Fiorentini et al., "Potential use of imatinib mesylate in ocular melanoma and liposarcoma expressing immunohistochemical c-KIT (CD117)," Annals of Oncology, Vol. 14, p. 805 (2003)

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.